Skip to search formSkip to main contentSkip to account menu

Viracept

Known as: Agouron Brand of Nelfinavir Mesylate, Roche Brand of Nelfinavir Mesylate 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Roche's protease inhibitor nelfinavir mesylate (Viracept®) produced between March 2007-June 2007 was found to contain elevated… 
2007
Review
2005
Review
2005
Nelfinavir (Viracept) is an orally administered protease inhibitor. In combination with other antiretroviral drugs (usually… 
2003
2003
This report deals with enantioselective synthesis of viracept 1 (nelfinavir mesylate, AG 1343), a potent HIV protease inhibitor… 
2002
2002
Summary Forty (40) HIV positive patients with CD4 cell counts between 100 - 500 cellh/mm3 were recruited from 8 different centres… 
Highly Cited
2001
Highly Cited
2001
ABSTRACT Nelfinavir mesylate (Viracept, formally AG1343) is a potent and orally bioavailable human immunodeficiency virus (HIV… 
2001
2001
Two studies, concerning the synthesis of original nucleoside analogs regarded as an application of heterochemistry on… 
Highly Cited
1999
Highly Cited
1999
A 32-year-old African American woman with human immunodeficiency virus 1 (HIV-1) and a 3-year history of extensive facial… 
1997
1997
  • J. James
  • AIDS treatment news
  • 1997
  • Corpus ID: 33336844
The Food and Drug Administration (FDA) approved nelfinavir (Viracept) for both adult and pediatric use for treatment of HIV…